BPON-02 Injection
创建时间：2022-05-13 17:31
|
Name/Code number |
BPON-02 Injection |
|
Category |
New Chemical Entity |
|
Mode of Action (MOA) |
GABAA receptor agonist |
|
Formulation |
Emulsion for injection |
|
Strengths |
TBD |
|
Indication |
Intravenous injection for induction of general anesthesia |
|
Stage |
Phase I (in China) |
|
Characteristics/Advantages |
1.As a derivative of Etomidate, BPON-02 has similar potency, and retains the advantage of Etomidate that exerts less influence on circulation and respiratory system
2.Has more stable anesthetic state and less time to wake up and recovery than that of Etomidate
3.No effects on the synthesis of corticosteroids, thus can be used for elderly and critically ill patients
4.A famous professor of anesthesia from Duke University gave a high evaluation for the compound
5.Global IP protection for the structure and related usages (US, EP, CA, CN, JP patents)
|
|
Cooperation Model |
Out-license for global market outside of China(China right has been out-licensed) |
